Incyte’s $1.25B Buyout Brings What Could Become the Next Big Bleeding Disorder Drug
Incyte’s Vega Therapeutics acquisition comes with a late-stage drug offering a novel mechanism of action and a dosing advantage compared to currently available therapies for von Willebrand disease, an inherited bleeding disorder. The deal comes as patent expiration looms for Jakafi, currently Incyte’s top product.
Vida Health Teams Up with Instacart to Expand Access to Nutritious Food
Vida Health partnered with Instacart to provide members with grocery stipends for healthy foods, expanding access to nutrition support as part of cardiometabolic care.
How AI is Unlocking Smarter Clinical Trial Protocols
By fine-tuning domain-specific models with real clinical operations data — such as historical performance, feasibility outcomes, enrollment patterns, and resource utilization — hidden information can be translated into structured intelligence.
6 Ways in Which Healthcare Needs to Expand the Supply Chain Resilience Conversation
Supply chain resilience is far too important to leave with the supply chain specialists. Health systems must elevate the resilience issue to the corporate strategy level and involve officers from other functional areas as well.
Expanding the Reach of Remote Patient Monitoring: The Real Signal Behind the 2026 RPM Changes
While the policy changes create new opportunities, they also introduce operational complexity. Here's some important things to know.